Gurkamal Chatta
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers 24
- Cancer Treatment and Pharmacology 20
- Immunology top 2%
- Immunotherapy and Immune Responses 28
-
- Prostate Cancer Treatment and Research 50
- Prostate Cancer Diagnosis and Treatment 14
- Cancer Research top 5%
- Hematology top 5%
- Multiple Myeloma Research and Treatments 9
-
- Bladder and Urothelial Cancer Treatments 19
-
- Radiopharmaceutical Chemistry and Applications 13
- Co-authors
- Michael R. ShurinDaniel P. PetrylakIrina L. TourkovaPrimo N. LaraGalina V. ShurinAnna LokshinMaha HussainDean G. Tang
- Partner nations
- United StatesCanadaGermany
In The Last Decade
Gurkamal Chatta
133 papers receiving 3.4k citations
Peers
Comparison fields: 5 of 115
- Oncology 1.3k
- Immunology 953
- Pulmonary and Respiratory Medicine 1.0k
- Cancer Research 450
- Hematology 277
Countries citing papers authored by Gurkamal Chatta
This map shows the geographic impact of Gurkamal Chatta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gurkamal Chatta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gurkamal Chatta more than expected).
Fields of papers citing papers by Gurkamal Chatta
This network shows the impact of papers produced by Gurkamal Chatta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gurkamal Chatta. The network helps show where Gurkamal Chatta may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Gurkamal Chatta, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 20 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 0 | |
| 5 | 2023 | 4 | |
| 6 | 2023 | 3 | |
| 7 | 2022 | 1 | |
| 8 | 2021 | 102 | |
| 9 | 2020 | 13 | |
| 10 | 2020 | 12 | |
| 11 | 2019 | 74 | |
| 12 | 2018 | 1 | |
| 13 | 2017 | 12 | |
| 14 | 2010 | 94 | |
| 15 | 2009 | 23 | |
| 16 | 2005 | 172 | |
| 17 | 2005 | 59 | |
| 18 | 2004 | 11 | |
| 19 | 2003 | 10 | |
| 20 | 2001 | 85 |
About Gurkamal Chatta
Gurkamal Chatta is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology, having authored 143 papers that have together received 3.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (50 papers), Immunotherapy and Immune Responses (28 papers), Cancer Immunotherapy and Biomarkers (24 papers), Cancer Treatment and Pharmacology (20 papers), Bladder and Urothelial Cancer Treatments (19 papers), Prostate Cancer Diagnosis and Treatment (14 papers), Radiopharmaceutical Chemistry and Applications (13 papers) and Multiple Myeloma Research and Treatments (9 papers). The work is most often cited by research in Oncology (1.3k citations), Immunology (953 citations) and Pulmonary and Respiratory Medicine (1.0k citations). Gurkamal Chatta has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Michael R. Shurin, Daniel P. Petrylak, Irina L. Tourkova, Primo N. Lara, Galina V. Shurin, Anna Lokshin, Galina V. Shurin, Maha Hussain, Dean G. Tang and Robert L. Ferris. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.